Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Salarius Pharmaceuticals Inc

Healthcare US SLRX

NoneUSD
-(-%)

Last update at 2026-02-12T21:10:09.358590Z

Day Range

--
LowHigh

52 Week Range

0.431.87
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap2.21M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.23641M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -15.83683M
  • Diluted EPS TTM-2.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -12.54269M -31.60796M -12.76824M -7.35225M -6.93810M
Minority interest - - - - -
Net income -12.54269M -31.37477M -12.70436M -7.09675M -5.60928M
Selling general administrative 5.72M 7.14M 6.10M 6.11M 7.71M
Selling and marketing expenses 5.71M - - - -
Gross profit -0.01005M -0.00668M 1.82M 5.23M 3.46M
Reconciled depreciation 0.01M 0.00668M 0.02M 0.02M 0.13M
Ebit -12.89494M -31.84114M -12.81293M -7.78634M -9.57641M
Ebitda -12.88489M -14.11710M -12.85762M -7.84825M -9.44900M
Depreciation and amortization 0.01M 17.72M -0.04469M -0.06191M 0.13M
Non operating income net other - - - 0.44M 1.31M
Operating income -12.89494M -31.84114M -12.81293M -7.78634M -9.57641M
Other operating expenses 12.89M 22.98M 14.65M 12.84M 11.73M
Interest expense - 0.23M 0.04M 0.00305M 0.00000M
Tax provision - - - - -
Interest income 0.36M 0.22M - - 1.33M
Net interest income 0.36M 0.22M -0.00329M -0.00305M 0.02M
Extraordinary items - - - - 0.00183M
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00000M -0.23318M -0.06388M -0.25550M -1.32881M
Total revenue 0.00000M 0.00000M 1.84M 5.23M 3.47M
Total operating expenses 12.88M 22.98M 14.65M 12.84M 11.73M
Cost of revenue 0.01M 0.00668M 0.02M 0.00691M 0.00402M
Total other income expense net 0.35M 0.23M 0.04M 0.43M 2.64M
Discontinued operations - - - - 0.00183M
Net income from continuing ops -18.03183M -31.60796M -12.76824M -7.35225M -6.93810M
Net income applicable to common shares - -31.60796M -12.76824M -7.74866M -6.93626M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6.59M 14.65M 40.83M 24.93M 13.89M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.62M 2.41M 0.95M 0.82M 0.96M
Total liab 1.30M 4.27M 2.11M 2.77M 3.31M
Total stockholder equity 5.29M 10.38M 38.72M 22.16M 10.58M
Deferred long term liab - - - - -
Other current liab 0.41M 1.41M 0.57M 0.06M 0.48M
Common stock 0.00039M 0.00022M 0.00452M 0.00238M 0.00045M
Capital stock 0.00039M 0.00022M 0.00452M 0.00238M 0.00045M
Retained earnings -76.34784M -63.80515M -32.19719M -19.42895M -12.07670M
Other liab - - - - -
Good will - 0.00000M 8.87M 8.87M 8.87M
Other assets 0.00000M 0.13M 1.80M 0.25M 0.31M
Cash 5.90M 12.11M 29.21M 11.12M 3.74M
Cash and equivalents - - - - -
Total current liabilities 1.30M 4.27M 2.11M 2.77M 3.31M
Current deferred revenue - - - 0.38M 0.54M
Net debt -5.61027M -12.10643M -29.21438M -10.64159M -3.23657M
Short term debt 0.29M - - 0.48M 0.50M
Short long term debt 0.29M - - 0.48M 0.50M
Short long term debt total 0.29M - - 0.48M 0.50M
Other stockholder equity 81.63M 74.19M 70.92M 41.59M 22.66M
Property plant equipment - - 0.00788M 0.02M 0.03M
Total current assets 6.52M 14.52M 30.16M 15.80M 4.69M
Long term investments - - - - -
Net tangible assets - 10.38M 29.86M 13.29M 1.71M
Short term investments - - - - -
Net receivables - 1.61M - 3.86M -
Long term debt - - - - -
Inventory - -1.61049M - - -
Accounts payable 0.60M 2.86M 1.54M 1.85M 1.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00238M 0.00045M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -19.42895M -12.07670M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.07M 0.13M 1.80M 0.25M 0.31M
Deferred long term asset charges - - - - -
Non current assets total 0.07M 0.13M 10.67M 9.14M 9.20M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.00000M -1.50000M -1.50000M -0.00260M 5.61M
Change to liabilities - 1.31M -0.31066M -0.54448M -0.83991M
Total cashflows from investing activities - -1.50000M -1.50000M -0.00260M 5.61M
Net borrowings - - -0.47703M -0.97444M -0.41789M
Total cash from financing activities 6.64M 1.99M 28.30M 17.69M 3.58M
Change to operating activities - 1.06M 0.10M 1.36M -0.22906M
Net income -12.54269M -31.60796M -12.76824M -7.35225M -6.93626M
Change in cash -6.20653M -17.10795M 18.10M 7.38M -2.39288M
Begin period cash flow 12.11M 29.21M 11.12M 3.74M 6.13M
End period cash flow 5.90M 12.11M 29.21M 11.12M 3.74M
Total cash from operating activities -12.84614M -17.59532M -10.20020M -10.31136M -11.58010M
Issuance of capital stock 6.92M 1.99M 27.29M 14.80M 4.13M
Depreciation 0.01M 0.00668M 0.02M 0.02M 0.13M
Other cashflows from investing activities - - - - 5.61M
Dividends paid - - - 0.00000M 0.13M
Change to inventory -0.00000M - -2.24551M 3.86M 0.00117M
Change to account receivables 1.48M - 2.25M -3.85600M 0.00069M
Sale purchase of stock - - - 18.67M -3.71290M
Other cashflows from financing activities 0.00664M 0.00199M 1.49M 3.87M 3.71M
Change to netincome - 11.64M 0.51M 0.06M -0.55971M
Capital expenditures 0.00000M 1.50M 0.00000M 0.00260M 0.00260M
Change receivables - - - -3.85600M 0.00069M
Cash flows other operating - - - 0.60M -3.37347M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 7.38M -2.39288M
Change in working capital -0.96833M 2.37M 2.03M -3.03801M -4.21153M
Stock based compensation 0.52M 0.80M 0.56M 0.32M 0.75M
Other non cash items 1.45M 10.84M -0.04469M -0.25855M -1.31133M
Free cash flow -12.84614M -19.09532M -10.20020M -10.31396M -11.58010M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SLRX
Salarius Pharmaceuticals Inc		 - -% - - - 18.12 0.41 0.14 0.27
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Salarius Pharmaceuticals Inc

2450 Holcombe Boulevard, Houston, TX, United States, 77021

Key Executives

Name Title Year Born
Mr. David J. Arthur M.B.A. CEO, Pres & Director 1963
Mr. Mark J. Rosenblum CPA Exec. VP of Fin. & CFO 1953
Dr. Nadeem Q. Mirza M.D., M.P.H. Sr. VP of Clinical Devel. NA
Dr. Daniela Y. Santiesteban Director of Targeted Protein Degradation Program NA
Mr. David J. Arthur M.B.A. CEO, President & Director 1963
Mr. Mark J. Rosenblum CPA Executive VP of Finance & CFO 1953
Dr. Nadeem Q. Mirza M.D., M.P.H. Senior Vice President of Clinical Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.